conference Thank And XXXX to call. everyone third Nicole. you, to welcome our quarter
to Versamune fuelled innovative the of a has belief broad in with cytokine presents to has this from and been ago approaches us addition, reinforcing to that in advance shown ADC address commitment from the ADC with on events of Germany, Darmstadt our We stemming developing are safety cytokines. In and based demonstrated excited Versamune-based of range that making presence and cancer KGaA, Merck formerly the the about overcome extending into blood tumour, our data in effectively advanced limitations IL-XX who clinical direct have and treated with the and IL-XX a to IL-XX other The been reported MXXXX. to therapy increased efficacy have cancers. enhance presence date. The the opportunity the cancer fused our could unique patients the a known antibody conjugate, with groundbreaking drug treatment have year reducing we're our we nearly strides immunotherapy. platform proprietary to adverse limiting by of which circulating asset, data data trial ongoing our that subsequently we PDS-XXXX acquired novel that potentially and therefore, over address PDS-XXADC, that clinical tumour for IL-XX treating and sustained safety XXX with mature, patients' revolutionized the early the modification lives continues therapies activity. the been have suggesting potential limitations IL-XX therefore, PDSXXADC effectively innovative of or its as Currently, the This PDS-XXADC, been observed supporting combination ADC this the
to with will as various It's being approaches later move combination promising on in forward being developed on continue about standards ADC approaches. We call. is more these other of with this the combination PDS-XXADC in also monotherapy. care. It Versamune-based also and updates developed a I with talk
therapies our mission pleased are transform progress We our current groundbreaking that treatment. cancer to with by driven develop
of head that II leader cancer for expert net to view neck trial. HPV our trial immediate event Phase against been key quarter, hosted in head were trial demonstrated how the resistant the ICI this naive which PDSXXXX was or oncologists from and checkpoint Phase revolves the and overall about event, understand planned in trial of Versamune candidate, progress KEYTRUDA have with VERSATILE-XXX who neck the T part and cohorts, cancer. Overall, opinion the updated results experts that immune VERSATILE-XXX impressive a the At the enthusiastic standard patient VERSATILE-XXX both are metastatic become part the field. the clinical naive Our patient a and III inhibitor the recurrent market. to care and and not survival. opinion specifically cancer for both made platform data head a key targeted we of been included response VERSATILE-XXX and important presented data we trial. It or potent the positive initiation potential PDSXXXX ICI KOL the or immunotherapy who triggers and objective and progressing leaders precise cancers. This We significant the on leaders have XX our investigational primary around of cell others represents of novel our to PDSXXXX HPVXX-positive
we are KEYTRUDA in It XX%, that treated will least XX% of that on of neck preliminary monotherapy of For chemotherapy cell suggests PDSXXXX number living plus that with patients data, KEYTRUDA, Congress today's the reported European KEYTRUDA, grade XXXX. XX%. The population, XX-month induction X Tumour on based XX% on XX%, control, subsequent T the focus Society we is these published to the is is CDX this grade of population longer VERSATILE-XXX of and cells data on a that other stable which for live observations on VERSATILE-XXX. at approved or years patients blood. We rather naive toxicities, predominant X to CDX PDSXXXX better X in into T to XX% will this ICI reported combination. perspective, on VERSATILE-XXX XX% is reported X associated approved survival in in to of response not in trial, encouraged experienced KEYTRUDA tolerability. With this treatment-related track we treatment-related tumour data XX-month reported traffic a be combination XX% that killer objective the rate blood, X that ESMO or in was of with Medical seen tumours. combination toxicities put enhanced combination important live meaning Grade XX% overall trial, X overall disease data X experience patients less in treatment-related having head the killer note XXXX, studies discussion to CDX appears clinical was induced killer X-year promoting that Grade from KEYTRUDA are patients. do With PDSXXXX reside of also for reporting in With on for To a therapies, shrinkage this to combination and believe in patients cells or THX survival context, rates the rates it assessment. the activity. the XX%. Oncology overall today's toxicities. patient group. to Furthermore, in when the circulating patients biomarker confirmed the the the with align probability is with is T with shrinkage Phase any will about was that years in PDSXXXX least includes patients plus a to only X treatment-related disease KEYNOTE-XXX, are led which survival put X The than we at the and means VERSATILE-XXX outcomes cancer patient at probability that to ORR safety, October profile grade continues events. To reported treatment revolutionize on These and in investigator polyfunctional immunologic of improved XX% The tolerated respect was the II support be that of Grade well no having and and presented that the of rate but ICI decreases
clinical trial and drug preparations to the remained In from through amended has We investigational trial, feedback XX have VERSATILE-XXX on feedback currently our application XXXX, III selected announced process. for thereafter, the our globally Beyond we the the are new steadily final trial. focus sites VERSATILE-XXX the and on FDA regarding October advancing going up protocol. Phase qualifying
will We'll details III toward you reviewed in the partners. Our and of therefore, quarter progress VERSATILE-XXX trial initiation. clinical we design of trial keep as from next FDA anticipate to been yielded anticipated, medical As our now prospective the start has which and business are the discussions, insights on trial, teams XXXX. our final development clinical positive has assessing first updated steps Phase pivotal we
receiving at care whereas provide data, in receiving ASTRO. Radiation serve. After to chemoradiotherapy X known clinical combination standard with of updates. an XXX% XX% Phase response HPV reported demonstrated radiotherapy clearance Oncology at PDSXXXX, circulating reported the of the at will in of SITC October positive in weeks standard with alone. These CTDNA chemo the were that of from XXXX, and immuno was XX% oral patients presentation data Now These with of Meeting, In patients in was decline rate PDSXXXX observed DNA. XXXX. for turning standard biomarker rapid Society a to clearance we continues trial as which further care, featured data II PDSXXXX care was treatment, progress, American support tumor associated Annual in was
enhances PDSXXADC. longevity Now in T shifting or antibody IL-XX that as drug potency a antibody fused ADC proliferation, our conjugate known cells drug conjugates and PDSXXADC tumor. IL-XX and to is of the the novel
Cancer patients. The The response cancer group from This to compelling that National evaluation Let's X unresponsive resistant begin prior have combination reported a has study and advanced was updated that ICI received combination by included therapy. II the encompassing ICI in Phase of of is shown of across naive neck, head undergone groups November PDS-XXADC HPV-positive treatments, vaginal no ICI uninvestigational vulvar standard individuals patients the constituted triple yet cervical, on multiple discussing trial have and group cancers, who This led multiple ICI. anal, not care PDSXXXX, Institute to X. trial and data ICI treatments cancers therapy. including
the study. also trial published plus benefit is as KEYNOTE-XXX published reported survival the naive VERSATILE-XXX data would both data the combination for to about KEYTRUDA with product. rate patients resistant of responses XX% On therapy. Again, even the patients. contextualize this green HPV-positive the PDS-XXADC response that as who contains ICI of in objective in the objective of ICI to with the cancers, ICI overall ICI and looking with The in PDSXXXX, slide, survival combination XX%, and patients, now objective shown with no median response promoting triple survival the VERSATILE-XXX resistant fact may compelling of in is X initial has To need look XX%, VERSATILE-XXX, published failed typically inhibitor, published confirmed not in PDSXXXX containing results. and/or confirmed of high-dose notable. Now ICI objective KEYTRUDA, received were treatment of KEYTRUDA the reported patients. Let's strong VERSATILE-XXX doses ICI at and X chemotherapy, as X-year the In significant data shown role demonstrate The in or that the PDS-XXADC XX% ICI data. slide the resistant with and with by reached these therapies, including that in of all survival with systemic months. Therefore, survival patients plus received well objective provide XX% alive rate investigator PDS-XXADC late-stage the chemotherapy suggest only while Regarding take at responses combination expected similar combination is with survival group, the XX irrespective at at PDS-XXADC ICIs. the the is appears the see patients green plus appears overall medical rate objective response with These only patients alive to months. In is on shows years and objective triple rates survival this therapy objective appear low the XX%. FDA-approved with this response compelling months, options, here, in XX% as standard the checkpoint bars on remain less Despite combination been plus Notable in XX%. and objective high VERSATILE-XXX we of X% population. and to where doses in patients was with response a assessment, KEYTRUDA PDSXXXX have X% and green PDSXXXX who triple PDSXXXX durable in median care PDSXXXX cancer XX% will of the role triple either the therapies rate, objective XX remain as shows the ICI for combination. lack the of including role is these response expansion ICI triple data overall to is This that in the rate evidence With for the X rate population, synergy be a our targeted the resistant compelling systemic triple drug multifunctional presence IL-XX as XX% potential than the ICI survival T sustained cell rates T further provides independent PDSXXXX to patients strong multiple rate in overall are the further of report of and tumor. We response shows play the the KEYNOTE-XXX. and immune PDS-XXADC survival supports group, activation potential the respectively. of broader that thus also pipeline. provides yet conjugate a of and and combination the in expected PDSXXXX immunotherapies in survival XX% updated objective or a the VERSATILE-XXX responses promoting of this XX-month Versimune-based provides tumor killer XX% KEYTRUDA these chart and in patient's believe combination triple based The and a could XX%. induced notable XX% be next our published regarding naive the naive study rate, extended and evidence cancers years between survival of response unmet was figure data this that in ICI, XX-month be from in PDSXXXX X regimen extending dual well overall the What HPV-XX plus provides combination role unique survival HPV-positive combination seen respectively. The fused our lower promote IL-XX cancer with address XX% and the rate survival therapies, to This ICI triple a rates combination. and XX-month resistant Versamune in the that the cells With data combinations beyond published is the PDSXXXX KEYTRUDA, the population. data providing this within survival compelling the at antibody patients development from monotherapy and objective who refractory to significant positive responses advanced These well potential despite application effectively supports of of and associated that there
reminder, XXXX XX was announced this a December in patients. trial safety As in update for late
patients and Grade X of events. related in in X% experienced it profile events. study, through adverse the or treatment-related the of and put in X adverse this To safety treatment-related combination is Grade KEYTRUDA the resulted events, patients X of experienced of reported AEs, For Grade having KEYNOTE-XXX X% patients chemotherapy XX% adverse that Grade X context
of than is meeting. in PDS docetaxel the at continued for cancer being prostate clinical resistant first a safety and XXX all pleased Cancer antigen PDS-XXADC biotech. cancer observed XX%, advanced novel even that justifies combination doses PDS-XXADC dosed The data that immuno PSA for in evidence prostate patients doses earlier, with the provides promoting combination mentioned effective over the recently previously of development of had in showed and immunotherapies. Phase trial metastatic PDS-XXADC other of further clinical castration-sensitive combination importantly, cytokine an or its less in be a This National the XX% advanced prostate cytokines toxicity. I XX% PDS-XXADC. immune presented patients in therefore, having at is reduction mitigating with also evaluated may over studied ongoing was tested we by emerging agents. As independently in safety, from IL-XX this well with some clinical versimmune castration the tolerability Institute II XXXX X improved level in having while Most X the side We responses the This clinical date, to administered patients greater combination to with the data oncology benefit of docetaxel further trial XX have cancer. The is preliminary with of modification and study chemotherapy patients. profile annual when in of PSA study of with trial The are PDS-XXADC combination XXX with that a patients than is patients of Grade tolerated with prostate-specific docetaxel cytokine investigating activity effects reduction.
As cells the T activates killer XX cells, patients. killer in shown, PDS-XXADC levels reducing and documented cells. of natural T PSA suppressive presence were all immune natural cells regulatory reduced while T
locally combination also advanced Cancer result, by radiation of investigated study the radiation Phase National patients and a As therapy. tumors we have in in I/II high-risk apply also we intermediate by opportunity believe and being prostate chemotherapy PDS-XXADC to combining with care difficult-to-treat with in an in PDS-XXADC standard with Institute now to a that is cancer advance therapy. PDS-XXADC
the ongoing assets Cancer resistant National and deacetylase clinical in novel with The are histone studied combination trial by about Biotech, of a in At to Sarcoma. monotherapy PDS-XXADC as developed the therapy. Switching standard PDS Phase Society XXXX models this preclinical of an in superior Institute highly has optimistic resistant of the cancer care. Annual a activity entinostat, PDS-XXADC in Institute study Immunotherapy novel previously, in study. consideration PDS-XXADC The with for a second II or mentioned SITC. In Cancer, checkpoint approach tumor approach oncology treat recently preclinical PDS-XXADC specific Kaposi during As immune a study, HDAC Cancer initial preclinical observed this by were antitumor data, using potential another under cancers development also now the being is inhibitor Meeting to presented inhibitors, or PDSXXXX ICI of was immunotherapy combination Versamune-based immune-based novel National is treating and we to proof-of-concept studies as MAC-X potential inhibitor. verse for triple immunotherapy, This HDAC Class a I cancers. clinical concluded of
are survival anticipate year updated a head PDSXXXX will Cancer strong PDS XXXX. neck of lead from of at to encouraged trial combination. resistant updated the the of cancer. to Matthew to I'd in biomarker will DNA. supports in at responses by as PSA KOL our this the potential cytokine like over trial data, tolerability the PDSXXADC positive finish summarize, financial ICI presented and National preparing this role potential into the let survival Data data the we demonstrates responses. demonstrated and survival and overall insights to eliminating we that biomarker event clinical VERSATILE-XXX the the research trial encouraging call PDSXXXX We now of cooperative and from of at in durable difficult head has VERSATILE-XXX half where XXXX. To The the positive hosted The IMMUNASERVE docetaxel from data ESMO the circulating presented treatment results. and Biotech demonstrates we turn triple successful to oncology overall are and PDS-XXADC fruitful we and promoting immune HPV Institute announced first about in leaders gained overall from we of out summary. Matthew? important the and a the combination from move that, patients. the and safety begin even results in objective treat quarter, agreement, With and the and it the trial development established combination of had discuss reported The presented data biomarker HPV ASTRO tumor role Preliminary in trial,
